We use cookies to provide you a better experience. By continuing to use this website, you consent to the use of cookies in accordance with our Cookie Policy.

Healthcare

Delivering solutions in M&A, Capital Raising, and Restructuring.

Healthcare Investment Banking Group

Finding financial solutions across every sector of the healthcare ecosystem.

A full-service healthcare investment banking practice offering a best-in-class combination of deep sector knowledge, strong industry relationships, and broad product expertise.

Stifel’s Global Healthcare Investment Banking Group is comprised of 47 professionals covering all segments of the healthcare industry. The team, located in New York, San Francisco and London, has substantial experience in assisting companies with all types of financing and M&A assignments. The Global Healthcare Group is dedicated to building long-term relationships with its clients through senior level attention. Since the formation of the Global Healthcare Group in Q4 2010, the team have helped raise over $79.1 billion for over 225 healthcare companies in over 440 transactions. Over the same period, members of the Global Healthcare Group have advised on over 105 announced M&A transactions, including over 30 cross-border assignments.

Our team provides clients with strategic advisory and capital-raising services designed to support growth companies and their investors during all stages of their development. We offer equity and debt capital markets services, including book running leading IPOs, follow-ons, and convertible note issuances. The Global Healthcare Group is supported by M&A advisory with extensive cross-border expertise, access to private capital markets through SPACs and 144A solutions, as well as activism defense and restructuring.

Areas of Expertise

Biopharma

The biopharma sector is advancing at an unprecedented pace, driven by innovation and growth from small to large companies across all stages of development and therapeutic areas. Stifel’s Biopharma team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our deep understanding of the biopharma landscape, and our extensive relationships and transaction experience.

Medtech

The medtech sector is advancing at an unprecedented pace, driven by innovation and growth from small to large companies across all medtech subsectors.   Stifel’s Medtech team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our deep understanding of the Medtech landscape, and our extensive relationships and transaction experience.

Healthcare Services

The healthcare services landscape is constantly shifting, driven by changes in regulations, reimbursement, and advancements in technology. Stifel’s Healthcare Services Team works to stay abreast of these changes and is ideally positioned to serve the needs of our clients in all types of financing and M&A assignments via relationships, recent mandates, and years of thought leadership a cross a board range of healthcare sub-sectors including Alternate Site, Behavioral Health, Payor Services, Pharma Services, and Physician Groups.

Healthtech

Technologies are rapidly advancing the automation of workflows across the healthcare ecosystem, the development and efficacy of treatments, and the way in which care is provided in-person and remotely.  Stifel’s Healthcare Technology team brings a wealth of M&A and financing experience advising companies delivering software, digital health, data-driven, and technology-enabled solutions to providers, payors, pharmaceutical companies, and patients.

Tools & Diagnostics

The life science tools & diagnostics sector is transforming at amazing speeds.  Enabled by a broad array of new technologies, our ability to better understand all facets of the human genome has improved exponentially; all the while being done at greater efficiency and dramatically reduced costs. This widening knowledge set is enabling faster and more productive drug discovery, disease diagnosis and AI-enabled prognostic clinical capabilities.  Stifel’s Life Science Tools & Diagnostics team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our broad domain expertise, deep understanding of the competitive landscape, and our extensive relationships and transaction experience.

Driving innovation with forward-thinking investment banking solutions.

Learn more about the Group

Notable Transactions

GH Research IPO

$ 160,000,000

Initial Public Offering
Biopharma | June 2021
RCSA M&A
Mergers & Acquisitions
Healthcare Services | June 2021
Outset Medical – Follow-on Offering

$ 366,000,000

Follow-on Offering
Medtech | April 2021
Evolus 04-2021

$ 98,325,000

Confidentially Marketed Follow-on Offering
Biopharma | April 2021
SeaSpine Holdings 04-2021

$ 100,912,500

Confidentially Marketed Follow-on Offering
Medtech | April 2021
Karuna Therapeutics Follow-on Offering

$ 287,500,000

Follow-on Offering
Biopharma | April 2021
Maravai Life Sciences 04-2021

$ 646,875,000

Follow-on Offering
Tools & Diagnostics | April 2021
Ionis Pharmaceuticals 04-2021

$ 550,000,000

Convertible Senior Notes
Biopharma | April 2021
ProQR Therapeutics 03-2021

$ 103,500,000

Confidentially Marketed Follow-on Offering
Biopharma | March 2021
Cti Biopharma 03-2021

$ 50,652,000

Confidentially Marketed Follow-on Offering
Biopharma | March 2021
Evofem Biosciences 03-2021

$ 30,000,000

Confidentially Marketed Follow-on Offering
Biopharma | March 2021
AVEO Oncology 03-2021

$ 48,000,000

Follow-on Offering
Biopharma | March 2021
X4 Pharmaceuticals – PIPE

$ 55,000,000

PIPE
Biopharma | March 2021
PhaseBio Pharmaceuticals 03-2021

$ 56,000,000

Confidentially Marketed Follow-on Offering
Biopharma | March 2021
Prometheus Biosciences 03-2021

$ 218,500,000

Initial Public Offering
Biopharma | March 2021
Xenon Pharmaceuticals 03-2021

$ 115,000,000

Confidentially Marketed Follow-on Offering
Healthtech | March 2021
Nurix Follow-on Offering

$ 160,425,000

Follow-on Offering
Biopharma | March 2021
Cutera – Convertible Notes

$ 138,250,000

Convertible Notes
Medtech | March 2021
Squadron – Alphatec M&A

$ 90,000,000

Has Invested in
Medtech | March 2021
KalVista 02-2021

$ 222,250,000

Follow-on Offering
Healthtech | February 2021
SQZ Biotechnologies 02-2021

$ 60,000,000

Follow-on Offering
Healthtech | February 2021
Centene – Senior Notes

$ 2,200,000,000

Senior Notes
Healthcare Services | February 2021
Rhythm Pharmactuticals 02-2021

$ 150,000,000

Follow-on Offering
Healthtech | February 2021
Sientra – Confidentially Marketed Follow-on Offering

$ 42,000,000

Confidentially Marketed Follow-on Offering
Medtech | February 2021
Angion Biomedica Corp 02-2021

$ 117,000,000

Initial Public Offering
Biopharma | February 2021
Bolt Biotherapeutics 02-2021

$ 264,500,000

Initial Public Offering
Biopharma | February 2021
Vor Biopharma 02-2021

$ 203,439,942

Initial Public Offering
Biopharma | February 2021
Gemini – SPAC Merger & PIPE
SPAC Merger & PIPE
Biopharma | February 2021
MaxCyte – PIPE

£ 40,000,000

PIPE
Biopharma | February 2021
Applied Genetic Technnologies 02-2021

$ 74,500,000

Confidentially Marketed Follow-on Offering
Biopharma | February 2021
DarioHealth Group 02-2021

$ 70,000,000

Private Placement
Healthtech | February 2021
Precigen 01-2021

$ 129,375,000

Confidentially Marketed Follow-on Offering
Biopharma | January 2021
Dyne Therapeutics 01-2021

$ 168,000,000

Follow-on Offering
Biopharma | January 2021
Athira Pharma 01-2021

$ 103,500,000

Follow-on Offering
Biopharma | January 2021
AdaptHealth Crop 01-2021

$ 264,000,000

Follow-on Offering
Healthcare Services | January 2021
AbCellera Biologics 12-2020

$ 555,450,000

Initial Public Offering
Biopharma | December 2020
908 Devices 12-2020

$ 149,500,000

Initial Public Offering
Tools & Diagnostics | December 2020
IGM Biosciences 12-2020

$ 200,000,000

Follow-on Offering
Biopharma | December 2020
Kura Oncology 12-2020

$ 345,080,500

Follow-on Offering
Biopharma | December 2020
Repligen 12-2020

$ 312,225,000

Follow-on Offering
Tools & Diagnostics | December 2020
Codexis 12-2020

$ 750,000,000

Follow-on Offering
Tools & Diagnostics | December 2020
Silverback Therapeutics 12-2020

$ 277,725,000

Initial Public Offering
Biopharma | December 2020
Maravai Life Science, Inc. 11-2020

$ 1,863,000,000

Initial Public Offering
Tools & Diagnostics | November 2020
SQZ Biotechnologies 11-2020

$ 81,176,464

Initial Public Offering
Biopharma | November 2020
Lux Health Tech Acquisition Corp. 10-2020

$ 345,000,000

Initial Public Offering
Medtech | October 2020
Eucrates Biomedical 10-2020

$ 104,796,260

Initial Public Offering
Medtech | October 2020
Ionis/Akcea 10-2020

$ 1,898,938,296

Mergers & Acquisitions
Biopharma | October 2020
Pulmonx Corporation 10-2020

$ 2,128,500,000

Initial Public Offering
Medtech | October 2020
Zogenix 09-2020

$ 200,000,000

Convertible Notes
Biopharma | September 2020
Athira Pharma 09-2020

$ 277,761,104

Initial Public Offering
Biopharma | September 2020
Dyne Therapeutics 09-2020

$ 267,696,966

Initial Public Offering
Biopharma | September 2020
Horizon Therapeutics 08-2020

$ 963,470,000

Follow-on Offering
Biopharma | August 2020
Elanco/Vetoquinol 08-2020

$ 140,000,000

Mergers & Acquisitions
Biopharma | August 2020
Dechra Pharmaceuticals/Elanco Animal Health Inc. 07-2020

$ 135,000,000

Mergers & Acquisitions
Biopharma | July 2020
Cerevel Therapeutics 07-2020

$ 445,000,000

PIPE
Biopharma | July 2020
Nurix Therapeutics 07-2020

$ 209,000,000

Initial Public Offering
Biopharma | July 2020
Genocea BioSciences 07-2020

$ 80,000,000

PIPE
Biopharma | July 2020
Atreca 07-2020

$ 120,000,000

Confidentially Marketed Follow-on Offering
Biopharma | July 2020
Currency volume represents full credit to each underwriter. All transaction announcements appear as a matter of record only. Stifel collectively refers to Stifel, Nicolaus & Company, Incorporated and other affiliated broker-dealer subsidiaries of Stifel Financial Corp.